Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NPCE 
Neuropace Inc (NPCE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NPCE (3-star) is a STRONG-BUY. BUY since 5 days. Simulated Profits (-1.20%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.75
1 Year Target Price $16.75
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 177.77% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 324.20M USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) 8 | Beta 1.9 | 52 Weeks Range 5.45 - 18.98 | Updated Date 09/17/2025 |
52 Weeks Range 5.45 - 18.98 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -29.29% | Operating Margin (TTM) -29.01% |
Management Effectiveness
Return on Assets (TTM) -12.39% | Return on Equity (TTM) -176.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 333576680 | Price to Sales(TTM) 3.66 |
Enterprise Value 333576680 | Price to Sales(TTM) 3.66 | ||
Enterprise Value to Revenue 3.77 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 33081500 | Shares Floating 22522876 |
Shares Outstanding 33081500 | Shares Floating 22522876 | ||
Percent Insiders 2.71 | Percent Institutions 82.07 |
Upturn AI SWOT
Neuropace Inc
Company Overview
History and Background
NeuroPace, Inc. was founded in 1997. It is a medical device company focused on developing and commercializing innovative therapies for neurological disorders. It achieved a pivotal milestone with the FDA approval and commercialization of the RNS System.
Core Business Areas
- RNS System Therapy: The company's core business revolves around the RNS (Responsive Neurostimulation) System, a closed-loop brain-computer interface designed to prevent seizures in patients with drug-resistant epilepsy.
Leadership and Structure
The leadership team consists of key executives responsible for overseeing different aspects of the business, including research and development, sales and marketing, and finance. The organizational structure is designed to support the company's focus on innovation and commercialization of its neurostimulation technology.
Top Products and Market Share
Key Offerings
- RNS System: The RNS System is NeuroPace's primary product. It is a responsive neurostimulation system designed to treat drug-resistant epilepsy by monitoring brain activity and delivering targeted electrical stimulation to prevent seizures. While exact market share figures are not publicly available, NeuroPace occupies a significant portion of the responsive neurostimulation market. Competitors include companies offering alternative epilepsy management solutions, such as vagus nerve stimulation (VNS) from LivaNova (LIVN) and deep brain stimulation (DBS) from Medtronic (MDT), as well as pharmaceutical approaches from various companies (e.g., UCB, Eisai).
Market Dynamics
Industry Overview
The market for epilepsy treatments is driven by the large number of patients with drug-resistant epilepsy. Technological advancements and the development of personalized therapies are key trends.
Positioning
NeuroPace is positioned as a leader in responsive neurostimulation for epilepsy. Its competitive advantage lies in its closed-loop technology and the ability to personalize therapy based on individual patient brain activity.
Total Addressable Market (TAM)
The TAM for epilepsy treatments, including devices like the RNS System, is estimated to be several billion dollars globally. NeuroPace is positioned to capture a portion of this market by offering a unique, personalized treatment option for drug-resistant epilepsy.
Upturn SWOT Analysis
Strengths
- Innovative technology (RNS System)
- Personalized therapy approach
- Strong clinical data supporting efficacy
- FDA approved device
Weaknesses
- High cost of the RNS System
- Limited market penetration due to cost and complexity
- Reliance on a single product
Opportunities
- Expanding indications for the RNS System (e.g., other neurological disorders)
- Increasing awareness and adoption of responsive neurostimulation
- Strategic partnerships and collaborations
- Geographic expansion
Threats
- Competition from alternative epilepsy treatments
- Reimbursement challenges from insurance providers
- Technological advancements by competitors
- Regulatory changes
Competitors and Market Share
Key Competitors
- LIVN
- MDT
Competitive Landscape
NeuroPace's advantage lies in its responsive neurostimulation technology, allowing for personalized therapy. However, competitors offer more established and widely adopted treatment options.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on sales of the RNS System and expansion of its market reach.
Future Projections: Future growth projections depend on analyst estimates and company guidance.
Recent Initiatives: Recent initiatives include expanding clinical trials, improving the RNS System, and increasing market awareness.
Summary
NeuroPace is a company focused on providing solutions to epilepsy, and more specifically, drug-resistant epilepsy. The company's RNS system has generated revenue, but the company needs to ensure they penetrate deeper into the market and deal with reimbursement issues. With its technology, Neuropace has the potential to keep a foothold in the epilepsy market. They will need to be aware of their competitors' movements and make sure they have a robust strategy to deal with them.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neuropace Inc. website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuropace Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.neuropace.com |
Full time employees 209 | Website https://www.neuropace.com | ||
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.